» Articles » PMID: 22200546

Characterization of Oxaliplatin-induced Chronic Painful Peripheral Neuropathy in the Rat and Comparison with the Neuropathy Induced by Paclitaxel

Overview
Journal Neuroscience
Specialty Neurology
Date 2011 Dec 28
PMID 22200546
Citations 102
Authors
Affiliations
Soon will be listed here.
Abstract

Anti-neoplastic agents in the platinum-complex, taxane, vinca alkaloid, and proteasome-inhibitor classes induce a dose-limiting, chronic, distal, symmetrical, sensory peripheral neuropathy that is often accompanied by neuropathic pain. Clinical descriptions suggest that these conditions are very similar, but clinical data are insufficient to determine the degree of similarity and to determine if they share common pathophysiological mechanisms. Animal models do not have the limitations of clinical studies and so we have characterized a rat model of chronic painful peripheral neuropathy induced by a platinum-complex agent, oxaliplatin, in order to compare it with a previously characterized model of chronic painful peripheral neuropathy induced by a taxane agent, paclitaxel. The oxaliplatin model evokes mechano-allodynia, mechano-hyperalgesia, and cold-allodynia that have a delayed onset, gradually increasing severity, a distinct delay to peak severity, and duration of about 2.5 months. There is no effect on heat sensitivity. Electron microscopy (EM) analyses found no evidence for axonal degeneration in peripheral nerve, and there is no upregulation of activating transcription factor-3 in the lumbar dorsal root ganglia. There is a statistically significant loss of intraepidermal nerve fibers in the plantar hind paw skin. Oxaliplatin treatment causes a significant increase in the incidence of swollen and vacuolated mitochondria in peripheral nerve axons, but not in their Schwann cells. Nerve conduction studies found significant slowing of sensory axons, but no change in motor axons. Single fiber recordings found an abnormal incidence of A- and C-fibers with irregular, low-frequency spontaneous discharge. Prophylactic dosing with two drugs that are known to protect mitochondria, acetyl-l-carnitine and olesoxime, significantly reduced the development of pain hypersensitivity. Our results are very similar to those obtained previously with paclitaxel, and support the hypothesis that these two agents, and perhaps other chemotherapeutics, produce very similar conditions because they have a mitotoxic effect on primary afferent neurons.

Citing Articles

Mitochondrial A Adenosine Receptor as a Mechanism for the Protective Effects of AAR Agonists on Chemotherapy-Induced Neuropathic Pain.

Doyle T, Janes K, Xiao W, Kolar G, Kolar G, Luecke H J Neurosci. 2024; 45(3.

PMID: 39653498 PMC: 11735668. DOI: 10.1523/JNEUROSCI.1268-24.2024.


Intrathecal lactate dehydrogenase A inhibitors FX11 and oxamate alleviate chronic constriction injury-induced nociceptive sensitization through neuroinflammation and angiogenesis.

Cheng H, Chen N, Chen W, Wu Z, Sun Y, Teng W J Headache Pain. 2024; 25(1):207.

PMID: 39587478 PMC: 11590346. DOI: 10.1186/s10194-024-01916-x.


Protective effects of and extract on oxaliplatin-induced neuropathy via modulation of NF-κB signaling.

Mahajan S, Sureja V, Kheni D, Dubey V, Bhupathiraju K, Alluri V Toxicol Rep. 2024; 13:101781.

PMID: 39512239 PMC: 11541817. DOI: 10.1016/j.toxrep.2024.101781.


Centralizing the Knowledge and Interpretation of Pain in Chemotherapy-Induced Peripheral Neuropathy: A Paradigm Shift towards Brain-Centric Approaches.

Cunha M, Tavares I, Costa-Pereira J Brain Sci. 2024; 14(7).

PMID: 39061400 PMC: 11274822. DOI: 10.3390/brainsci14070659.


Current understanding of the molecular mechanisms of chemotherapy-induced peripheral neuropathy.

Chen X, Gan Y, Au N, Ma C Front Mol Neurosci. 2024; 17:1345811.

PMID: 38660386 PMC: 11039947. DOI: 10.3389/fnmol.2024.1345811.


References
1.
Windebank A, Grisold W . Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008; 13(1):27-46. DOI: 10.1111/j.1529-8027.2008.00156.x. View

2.
Holmes J, Stanko J, Varchenko M, Ding H, Madden V, Bagnell C . Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci. 1999; 46(2):342-51. DOI: 10.1006/toxs.1998.2558. View

3.
Krishnan A, Kiernan M . Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve. 2006; 35(3):273-90. DOI: 10.1002/mus.20713. View

4.
Renn C, Carozzi V, Rhee P, Gallop D, Dorsey S, Cavaletti G . Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol Pain. 2011; 7:29. PMC: 3105941. DOI: 10.1186/1744-8069-7-29. View

5.
Xiao W, Zheng F, Bennett G, Bordet T, Pruss R . Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. Pain. 2009; 147(1-3):202-9. PMC: 2787910. DOI: 10.1016/j.pain.2009.09.006. View